Exelixis | EXEL - Ebitda





Ebitda Veränderung Datum
Acadia Pharmaceuticals USD -1.62M 21.94M 2026-03
Agios Pharmaceuticals USD -108.66M 11.65M 2026-03
Akebia Therapeutics USD 14.03M 17.19M 2025-03
Amgen USD 3.86B 1.28B 2026-03
AstraZeneca USD 5.16B 510M 2026-06
Bayer EUR 2.14B 2.31B 2026-06
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Bristol-Myers Squibb USD 4.24B 1.37B 2026-03
Cytokinetics USD -169.32M 19.48M 2026-03
Eisai JPY 34.15B 34.48B 2026-06
Eli Lilly USD 10.29B 1.86B 2026-03
Exelixis USD 255.4M 2.89M 2026-06
Genmab DKK 401M 186M 2026-06
Glaxosmithkline GBP 2.77B 1.98B 2026-03
Incyte USD 778.57M 410.6M 2026-06
Ionis Pharmaceuticals USD -64.53M 135.49M 2026-03
MacroGenics USD -30.2M 52.15M 2026-03
Merck USD -1.54B 7.84B 2026-03
Moderna USD -1.26B 468M 2026-03
Nektar Therapeutics USD -38.9M 7.09M 2026-03
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Novartis USD 6.48B 1.19B 2026-06
Pfizer USD 6.01B 18M 2026-06
Puma Biotechnology USD 729K 11.36M 2024-06
Sanofi EUR 2.72B 2.94B 2026-03
Takeda JPY 364.46B 214.21B 2026-06
Ultragenyx Pharmaceutical USD -155M 55.57M 2026-03
Xencor USD -34.63M 86.74M 2026-06